Oncology Medication Utilization and Stewardship for the Health System
Originally presented at HOPA's 14th Annual Conference, March 2018.
In 2020, the cost of cancer care is projected to hit $158 billion, and drug expenses contribute significantly to this total cost of care. In the absence of a nationally accepted value matrix and value threshold, health systems, with the support of their clinical leaders, are left to determine and define what are patient-centered, sustainable, and evidence-based oncology medication utilization practices. In doing so, we always strive to keep the cancer patient at the center of care. In this session we will review the current state of value-based oncology care in the United States, seek to understand existing financial data for some oncology medications, discuss existing value matrices and tools, and engage in conversation about feasible solutions and best practices. Although we currently have no readily defined solutions for tackling the issues of cost, consumerism, and sustainability of cutting-edge oncology practice, we must continue to consider these big-picture topics if we are to influence the course of utilization, the culture of care, and planning for sustainable, value-based practice.
Chelsea Manion, PharmD BCOP BCPS
Patient Administration & Development
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by March 22, 2021.
This activity has been approved for .1 CEU
This course is also included as part of the Best of 2018 Annual Conference Recordings Bundle.
Release Date: September 26, 2018
Expiration Date: March 22, 2021